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Abstract
Palliative care (PC) that has evolved from a focus on end of life care to an expanded form of 
holistic care at an early stage for patients with serious illnesses and their families is commonly 
referred to as nonhospice PC (or early PC). Patients with end stage liver disease (ESLD) suffer 
from a high symptom burden, deteriorated quality of life with uncertain prognosis and limited 
treatment options. Caregivers of these patients also bear the emotional and physical burden 
similar to cancer caregivers. Despite proven benefits of nonhospice PC in other serious 
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integration within the routine care of ESLD patients and their caregivers. In this article, we 
review the current state of PC within ESLD, and propose key structures and processes to 
integrate nonhospice PC within routine hepatology practice. 
Results found that PC is highly underutilized within ESLD care, and limited prospective studies 
are available to demonstrate methods to integrate PC within routine hepatology practices.  
Hepatology providers reported lack of training to deliver PC along with no clear prognostic 
criteria on when to initiate PC. A well informed model with key structures and processes for 
nonhospice PC integration would allow hepatology providers to improve clinical outcomes, 
ESLD patients’ quality of life, as well as reduce healthcare costs. Educating the hepatology 
providers about PC principles and developing clear prognostic criteria for when and how to 
integrate PC based on individual patient needs are the initial steps to inform the integration. The 
fields of nonhospice PC and hepatology have ample opportunities to partner clinically and 
academically. 
Introduction
      End stage liver disease (ESLD) is the 12th leading cause of death and claims approximately 
66,000 lives each year in the United States (US). 1 Between 2006 and 2016, the prevalence of 
ESLD increased by 7.9% among men 25-34 years and 11.4% among women in the same age 
group due to increasing burden of non-alcoholic steatohepatitis (NASH), alcohol-related liver 
disease, and advanced hepatitis C virus (HCV). 2 In parallel, mortality due to ESLD increased by 
65% from 1999 to 2016.3 
     ESLD is also associated with functional and cognitive impairment, often with concomitant 
mental health and substance use disorders. The physical and psychological symptom burden 
and social role consequences of ESLD is often worse than many non-liver cancers. 4 The most 
frequently reported symptoms include pain, breathlessness, muscle cramps, sleep disturbance, 
fatigue, pruritus, anxiety, depression, and erectile dysfunction. 4 In addition to its direct effects 
on patients, ESLD is linked with substantial caregiver emotional and physical burden, mirroring 
that observed in caregivers of patients with cancer.5 However, interventions to improve patients’ 
with ESLD and their caregivers’ quality of life (QOL) are under-developed.
     Palliative care (PC) is the most promising solution to address the physical, psychological, 
and caregiver burden of ESLD. The aim of PC is to provide holistic care for patients with serious 
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advance care planning (ACP) and end-of-life care or hospice. Whereas hospice is considered 
for patients with projected life expectancy of less than 6 months, nonhospice PC is inclusive of 
all the other elements of PC applicable from the time of diagnosis onwards, for any serious 
illness. 6 Nonhospice PC has been clearly defined recently (Table 1). Unfortunately, there is 
suboptimal understanding of the structures and processes required to integrate nonhospice PC 
within hepatology. The goal of this review is to synthesize recent literature regarding the current 
state of PC for patients with ESLD, and propose key structures and processes required to 
integrate nonhospice PC within hepatology practice. 
Palliative Care Overview
      
Palliative care is a subspecialty focusing on patients’ individual needs (including physical, 
psychosocial and spiritual). Early PC has been shown to improve patient symptoms, QOL, 
patient satisfaction, advance care planning (ACP) discussions, reduce health care 
costs/utilization particularly intensive medical care and caregiver burden (Table 2).7 More 
recently, several non-cancer societies have recommended early introduction of PC for chronic 
illnesses such as end stage renal disease, heart failure and lung disease 8; however, no such 
guidelines exist in the liver disease literature. 9
Current state of Palliative Care in ESLD 
Several studies within the past 5 years identified limited availability of PC services for liver 
disease patients, leading to limited and late involvement of PC specialists, by which many 
potential benefits of PC may be lost.10 In an analysis of the nationwide inpatient sample, Rush et 
al found only 4.5% of all ESLD-related admissions received PC consult, although this increased 
from 1.0% in 2006 to 7.1% in 2012.11 Barnes et al found only 19% of eligible patients (defined 
as  2 admissions within 6 months for decompensated cirrhosis, excluding those who were 
listed for liver transplantation) received “early PC” (i.e. PC received >30 days prior to death), 
with hospitalizations costs significantly reduced in those with early PC due to a lower number of 
endoscopies and blood transfusions.12 Similarly, studies have shown that less than 20% of 
patients removed from the liver transplant (LT) waiting list receive PC consult, and most of those 
occur within 72 hours of death in an inpatient setting.13 A provider survey conducted among 
Veterans’ practices found that despite 82-88% practices having PC available on site, less than 
25% of ESLD patients were referred for PC consultation.14 Commonly reported barriers were 
insufficient staff knowledge about PC, uncertainty of timing to make PC referrals, and patient 















This article is protected by copyright. All rights reserved
care). A study from Canada reported less than 20% of patients with cirrhosis had ACP 
documented, despite a public awareness campaign raising awareness of ACP within the 
province, and almost 66% of patients were listed as being full code despite a dismal 
prognosis.15 However, patients preferred to have ACP discussions when they were still well, not 
wait till their health completely declines, and with the physicians they have ongoing relationships 
such as their hepatologists. 
Few prospective studies have tested nonhospice PC for ESLD, and some are ongoing (Table 
3). Of the few prospective studies, 50% are single arm uncontrolled studies. Only 1 RCT has 
been completed, but that was terminated due to under enrollment. However, all studies have 
supported feasibility, and positive patient outcomes.  
Barriers to Implementing PC
Barriers to include PC within routine hepatology practice can be categorized into those related 
to patients, providers and health systems. 
1. For patients, many see PC being synonymous with end-of-life care. The fear that PC 
may exclude them from liver transplant candidacy makes patients and their caregivers 
less willing to receive PC consultation. Hepatic encephalopathy can make the patients 
unable to participate in PC discussions such as goals of care or ACP.16
2. For providers, barriers include uneasiness in including PC consultants, misperception of 
PC being just end-of-life care, insufficient guidelines for PC integration, inadequate 
access to PC providers coupled with deficiency in PC provider workforce, insufficient 
time during routine clinical care for complex discussions, inadequate training in goals of 
care discussions or psychological/ symptom management, and a preferential focus on 
life-saving interventions.17 Fear of upsetting patients, not wanting to abandon them, 
considering PC referral as an admission of failure/ no hope, impaired patients’ cognitive 
capacity to participate in provider-led discussions, and providers not completely 
understanding the benefits of PC are other reasons.4
3. For health systems, implementation and policy barriers have been identified.18 
Implementation barriers include limited number of providers with PC training, challenges 
of identifying patients for appropriate PC referral at the systems level, and the need for a 
culture change across settings. Policy barriers include fragmented healthcare systems, 
lower profit margins in reimbursements for PC services, need for a pre authorization in 
some states and insurance carriers, inability to cover the uninsured, and lack of 
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towards patient-centered care, health systems are looking for options to improve patient 
satisfaction, and PC has proven to be one of them. 
Structures and Processes required for integrating Nonhospice PC in ESLD 
Models of nonhospice PC differ in their level of integration (e.g. freestanding or embedded PC 
clinics, inpatient PC consultation or a dedicated inpatient PC unit) and place of delivery of 
palliative care (e.g. inpatient, outpatient, home based or remote/using telehealth).  Table 4 
outlines the model structures and their potential strengths and weaknesses.  Timely, integrated 
PC requires contact at a time when the patients are functional, independent, and have 
supportive care needs. This is not a prognosis-based decision but rather a patient or family 
caregiver needs based decision. This type of care has been shown to be most effective at the 
time of outpatient visits, making outpatient clinics an ideal setting for nonhospice PC.19 However 
many different models exist that are tailored to overcome geographic barriers, work force 
shortages, etc. (e.g., virtual clinics, telehealth).  
The structures and processes to enable the heterogeneous PC models may vary. However 
there are basic elements which must be the part of a PC intervention. 20 These elements 
include:  
1. Patient- and family-centered care: Patient centered care, defined as health care which is 
inclusive of informed, respected and involved patients, is one of the six key elements of high 
quality care according to the Institute of Medicine.21 Optimal nonhospice PC engages patients 
and caregivers in decision making, prognosis understanding and preparedness for acute 
decompensation events. An example is the ENABLE model (Educate, Nurture, Advise, Before 
Life Ends) which has demonstrated effectiveness in oncology and heart failure.22 The 
intervention included an in-person PC assessment, weekly telehealth coaching sessions with 
advance practice nurses for 6 weeks for patients and 4 weeks for caregivers on select topics 
such as problem solving, symptom management, communication and decision making.  The 
qualitative programmatic evaluation found that participants gained illness management and 
decision making skills while continuing with curative treatments, and reported feeling 
empowered and experienced better care planning. 23
2. Inter-professional team: PC assessments target physical, psychological, social, spiritual 
and cultural needs of patients. An interprofessional team, usually comprised of a PC physician, 
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tackle the multidimensional needs of patients and caregivers.23 Team efficiency is featured by 
good leadership, effective decision making, and communication among team members. There is 
no evidence available to support which discipline optimizes the efficacy of PC. Interprofessional 
PC teams have improved patient’s health outcomes (such as symptoms and survival); however, 
no study has compared interprofessional teams with a solo practitioner approach.24  
3. Provider characteristics: Conventionally, a trained PC specialist provides PC when 
consulted, often referred to as “specialist/ consultative PC”. However, given the shortage in PC 
providers, high value and demand of PC, and the need to reduce care fragmentation, the 
concept of primary PC has gained importance. This includes basic skills that all clinicians should 
have i.e. basic management of pain and symptoms; depression and anxiety; basic discussions 
on prognosis, goals of care, suffering and code status. 25 Web-based online PC training has 
been described as a pragmatic approach, given the time constraints of most providers, and has 
demonstrated enhanced patient care.26 A study testing an online curriculum demonstrated 
improved confidence, knowledge and satisfaction of primary care providers in offering PC to 
their patients. 27 A randomized controlled trial demonstrated improved patient symptoms in the 
group receiving PC from primary care physicians trained in PC versus primary physicians not 
trained in PC. 28 Similar results have been seen in specialists trained in PC. For example, a 
nephrologist-led PC study showed significant increase in documentation of patient preferences 
for cardiopulmonary resuscitation and limits on life-sustaining treatment.29  
It is expected that hepatologists are aware of patient prognosis and treatment options, whereas 
PC specialists may not be fully aware of those including transplant eligibility, which can change 
over time. With appropriate training, hepatologists can provide evidence-based PC to their 
patients with supportive care needs (e.g., advanced care planning, goals of care 
communication, symptom management) in addition to offering all appropriate advanced 
therapies for patients with ESLD as routine practice. 
4. Screening tools to aid PC intervention at an early stage of ESLD: It is important to 
identify ESLD patients who may benefit from nonhospice PC early in their disease trajectory. 
Screening tools have been developed and validated to help identify patients for whom PC can 
be triggered in other settings such as emergency departments. However, few tools exist to 
identify unmet needs among ESLD patients. One such tool for ESLD inpatients at high risk of 
dying within 1 year includes 5 criteria: Child-Pugh class C, more than 1 liver-related admissions 
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unsuitability for liver transplantation and WHO performance score 3 or 4; a cumulative score > 3 
can be used to trigger PC referral. 30 Other more general screening tools can be applied to 
ESLD patients such as ED-PC (Emergency Department- Palliative Care), which includes three 
simple criteria: 1) presence of a life-limiting illness, 2) unmet PC needs (e.g. symptoms, 
functional decline, frailty, new onset of complications, limited social support) and 3) hospital 
admissions. 31
To intervene at an early stage of illness, it is important to use screening tools as standard 
practice. However, feasibility of including these screening tools within Hepatology practices 
needs further evidence. Instruments such as ESAS (Edmonton Symptom Assessment Score) 
for symptoms, PHQ-9 (Patient Health Questionnaire) for depression, and DT (Distress 
Thermometer) for distress can also be utilized.  ESAS assesses pain, fatigue, nausea, 
depression, anxiety, drowsiness, appetite, feeling of wellbeing, shortness of breath and others 
(including disease specific symptoms such as muscle cramps, itching, sexual function, and 
sleep). PHQ-9 includes 9 questions assessing depression, with higher scores reflecting greater 
severity of depression.  DT is a brief valid instrument to assess the severity of psychosocial 
distress in patients with serious illnesses, and helps initiate conversations about the wide range 
of difficulties, services and resources that may help address them.  
5. Goals of care discussions: Effective communication is the key to eliciting patient’s personal 
goals and preferences, and aligns those with their care management plans. Research has 
shown that communications about goals of care lead to improved patient’s health outcomes and 
reduced intensity of end of life care acts. These should be conducted at an early stage of 
illness, such as once a diagnosis of cirrhosis is made, but can change over time so must be 
revisited. The hepatology team can play a pivotal role in eliciting these goals. 32 However, clear 
evidence on how much of these discussions happen during routine hepatology consultations 
remains unclear. There are standard educational courses available to learn about goals of care 
such as VitalTalk and OncoTalk, which have been widely used to improve communication skills 
among providers.33 These are based on effective communication strategies to elicit and deliver 
personalized care. These can be a part of faculty development within Hepatology. Furthermore, 
a framework such as REMAP tool (Reframe, Expect emotion, Map out patient goals, Align with 
goals, and Propose a plan) can be utilized by the hepatology team to improve goals of care 
discussions.34  
6. Advance care planning is a mechanism of developing future health care goals, to be 
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explain the patients’ current health situation in a broader context of overall trajectory of liver 
disease, treatment options and potential outcomes associated with each (disease and 
treatments). In addition, these discussions ameliorate surrogate decision makers anxiety and 
depression, and reduce unwanted care acts towards end of life. A framework tailored to 
cirrhosis outlining the best practice tools for ACP has been published by Brisebois etal.35  They 
outline the key elements of ACP process as 1) elicitation of patient’s perspectives, 2) assess 
readiness to discuss ACP and choose a surrogate person, 3) educating patients (using 
educational resources on cirrhosis and its complications), 4) describing the focus of care to be 
inclusive of curative therapy and symptom management, 5) discuss prognosis using tools which 
include comorbidities, 6) review liver disease complications, 7) review available local resources 
for patients and their families, and 8) document goals of care.  For compensated cirrhosis, 
eliciting patients’ health goals are important. As they enter decompensated phase, in depth 
discussions on prognosis, treatment options and symptoms is warranted. Brisebois and 
colleagues recommend these discussions to occur irrespective of LT eligibility. 
7. Concurrent care models 
In 1990 the World Health Organization was the first to propose a concurrent care model in 
which PC was offered from the time of diagnosis of cancer. 36This was without evidence until the 
2000s when multiple studies in cancer have demonstrated PC effectively improved patients 
QOL, symptoms, and surprisingly, survival. 7Similarly, although PC and liver transplantation are 
often viewed as mutually exclusive a concurrent care model may prove beneficial. 37 Especially 
for ESLD patients who have the hope for transplant but risk of surgery, organ rejection, 
infection, and post-transplant morbidity in the setting of already diminished QOL pre-transplant, 
PC can optimize care. A quality improvement study in a VA setting, designed to proactively 
identify patients with a MELD 14, and/or HCC were referred for a PC consult through a care 
coordinator. 38 The results showed that PC consults improved the likelihood for considering for 
LT and the likelihood of completing the transplant evaluations. Telehealth could potentially be 
utilized to integrate PC within LT care, as has shown to work within liver practices. 39 
Another prospective study conducted in a surgical ICU for LT patients, tested a 2-part 
intervention of interdisciplinary communication between providers and patients/ families: family 
support, goals of care discussion and prognosis at admission and a follow-up interdisciplinary 
family meeting 72 hours later. 40 The intervention increased goals-of-care discussions (2% to 
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mortality.  The authors concluded that concurrent PC can be delivered in a surgical ICU setting, 
and can potentially improve end-of-life care. However, there is a high need to educate LT 
providers on PC benefits for patients and their caregivers. 
8. Caregiver support: Caregivers of ESLD patients have high rates of undiagnosed clinical 
depression; and higher burden is observed among those who care for patients with frequent 
hospitalizations, hepatic encephalopathy, or active alcohol use.41  Bajaj and colleagues reported 
increased caregiver burden, especially for those whose liver disease severity was high.42 This 
increased burden in general has been linked to increased mortality in addition to depression and 
anxiety. Research shows that caregivers who received PC were less likely to have depression 
or grief.43 Through nonhospice PC, caregivers can be evaluated for burden and distress, and 
linked to additional supportive resources. This may prove to be beneficial for both caregivers 
and their patients. 
Key steps to integrate nonhospice PC into ESLD care
Based on the above described structures and processes, and the current situation of 
nonhospice PC, there are 5 things which can be applied to improve PC integration within the 
treatment of ESLD: 
1) Provider education on nonhospice PC, as brief courses or an integral part of their 
fellowship training. 
2) Universal use of prognostic tools and screening of symptoms, depression, and distress 
within routine care, coupled with predetermined alerts to promote PC service.   
3) Develop clear criteria for PC referrals such as MELD (Model for End Stage Liver 
Disease) score, occurrence of an acute decompensation event, development of HCC 
beyond an early stage, number of hospitalizations and presence of comorbidities.
4) Include goal of care and advance care planning discussions as a part of routine ESLD 
care including at the time of transplant evaluation, wait-listing or delisting, or when no 
other curative options exist. 
5) Identifying methods to assess and address caregiver burden, QOL and distress 
separately from patients, coupled with referrals made based on the evaluations
PAL LIVER study (Introducing PC within the treatment of ESLD) 
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advance care planning approaches.  One of these is targeting ESLD population. The PAL 
LIVER study (Palliative Care for Liver Diseases) aims to compare a Consultative PC model to 
trained hepatologist-led PC delivery. It is a multi-center cluster randomized study, with clinical 
centers as the unit of randomization. 44 The primary hypothesis is that the trained hepatologist 
led PC model will have better improvement in QOL (from baseline to 3 months) than the 
Consultative model. Delivering PC in the context of routine hepatology care will build upon an 
established relationship between the patient and his/her hepatologist.  Furthermore, it will be 
more pertinent given the hepatologists’ understanding of the disease process; that includes the 
prognosis and ramifications of each complication.
A PC training program tailored to liver diseases has been developed to formally train hepatology 
providers in the Model 2. The study is currently enrolling (ClinicalTrial# NCT03540771), and 
recruits dyads (i.e. patients and caregivers together). The intervention is tailored towards both 
patients and caregivers, and utilizes a PC checklist for all study visits. The visits are billed to 
insurance, given the pragmatic nature and an aim to inform real world practice. The study has 
brought the two specialties: palliative care and hepatology together, to partner and improve the 
care of ESLD patients and their caregivers. Through this collaboration, the study has been able 
to implement both models in distinct settings. The results are projected to improve 
understanding of optimal integration of PC into clinical workflow. However, conducting PC 
research has its own inbuilt challenges. Some ongoing challenges to recruitment include: 
Patient factors- health related (such as uncertain prognosis/ complications, physical and mental 
challenges, patient not too sick, or doesn’t understand the value of PC) and social barriers (fear, 
resistance, additional time and travel); Caregiver factors- such as mistrust, limited information, 
beliefs, fear of intrusion, false hopes; and Provider factors- such as time sensitivity, work load, 
and other competing priorities.
Conclusions
Nonhospice PC is underutilized in ESLD care, despite a great need and potential to improve 
patient and family members’ QOL and reduce costs. Significant barriers exist with an unclear 
understanding of how to integrate PC within the treatment of ESLD. The structures and 
processes described in this review can guide the development of programs and interventions to 
improve nonhospice PC integration within ESLD care. The provision of training on PC for 
hepatology trainees and established practitioners will facilitate the implementation of this 
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in the care of ESLD can lead to an improvement in patients' quality of life and demystify some of 
the key challenges to support PC integration. 
Future Research:
Future collaborative research needs to continue between nonhospice PC and hepatology to test 
effective PC education approaches for hepatologists’; delineating clinical criteria which can 
trigger PC services for ESLD patients, advanced practice providers delivering PC within 
Hepatology offices given the busy schedules and limited time with hepatologists, or using 
telehealth based PC approaches. Furthermore, it will be important to identify which ESLD 
subgroups benefits the most from PC, how much PC can be delivered by hepatologists, and the 
optimal methods of conducting routine assessments of symptoms, depression, and distress 
within routine hepatology practices. Finally and critically, it is important to understand the 
financing of additional PC services within hepatology practices, supporting value-based 
medicine as opposed to a fee-for-service approach. 
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